Saturday 17 October 2026
Export FLGT’s income statement to Excel — free account
Fulgent Genetics, Inc.
FLGT Healthcare Diagnostics & Research
Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4.38%, EPS fell 69.4% and free cash flow grew 25.4%, each against the same quarter a year earlier.
19.81
1.53
−7.17%
Follow FLGT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.20 | 2.51 | 1.53 | 1.77 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
62.57 | (10.35) | 69.19 | (24.19) | |
P/B ratio |
0.62 | 0.73 | 0.47 | 0.58 | |
Price to Tangible BV |
0.72 | 0.80 | 0.54 | 0.67 | |
EV/Sales |
1.08 | 1.53 | 0.74 | 1.05 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
223.29 | (4.85) | (2.62) | (4.05) | |
EV/FCF |
(17.14) | (3.97) | (2.08) | (3.26) | |
Quick Ratio |
6.17 | 4.95 | 3.83 | 4.49 | |
Current Ratio |
7.01 | 6.48 | 5.31 | 6.34 | |
Net Debt/EBITDA |
778.06 | 8.20 | 9.36 | 8.82 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.26 | 0.27 | 0.27 | 0.28 | |
Operating CF/Net income |
(1.68) | 3.34 | (0.29) | 0.80 | |
Capex/Depreciation |
(0.41) | 1.05 | (1.02) | (0.56) | |
Interest Coverage |
(548.21) | (2,264.87) | (2,036.59) | (611.41) | |
Research and Development Expense of Revenue |
16.49% | 17.00% | 19.93% | 17.04% | |
Selling, General and Administrative Expense of Revenue |
41.61% | 63.15% | 56.10% | 49.68% | |
Intangible Assets out of Total Assets |
0.13 | 0.07 | 0.12 | 0.12 | |
Share Based Compensation of Revenue |
11.56% | 11.13% | 13.90% | 10.10% | |
Graham Net Nets |
0.60 | 0.55 | 0.75 | 0.63 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.15%) | (7.46%) | (15.03%) | (13.74%) | |
Free Cash Flow Yield |
(2.86%) | (15.36%) | (23.05%) | (18.06%) | |
Revenue per Share |
2.73 | 2.71 | 2.30 | 3.05 | |
Operating CF per Share |
0.36 | (2.54) | 0.23 | (0.85) | |
Capex per Share |
(0.20) | (0.16) | (0.17) | (0.14) | |
Free Cash Flow per Share |
0.16 | (2.70) | 0.06 | (0.99) | |
Cash per Share |
12.22 | 10.92 | 8.95 | 9.18 | |
Shareholders Equity per Share |
36.45 | 35.96 | 33.81 | 35.56 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
36.45 | 35.96 | 33.81 | 35.56 | |
Free Cash Flow |
5.06 | (83.12) | 1.90 | (27.62) | |
Working Capital |
434.95 | 465.52 | 388.91 | 383.01 | |
Capital Expenditures |
(6.05) | (4.98) | (5.19) | (3.86) | |
Net Current Asset Value |
413.57 | 443.68 | 366.83 | 361.53 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.07 | 0.06 | 0.07 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
64.25 | 76.89 | 70.38 | 71.06 | |
Average Payables |
18.95 | 18.51 | 19.68 | 17.22 | |
Average Assets |
1,224.16 | 1,216.74 | 1,181.06 | 1,144.53 | |
Average Common Equity |
1,127.83 | 1,117.94 | 1,083.46 | 1,053.81 |
Columns are period end dates